Clinical Trial Update: A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase II clinical trial evaluating oral Lucitanib in FGFR1-amplified or non-amplified estrogen receptor-positive metastatic breast cancer has completed, with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Lucitanib (Lucitanib)

Snippet

Sponsor: Institut de Recherches Internationales Servier | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED